Hillsboro, Oregon – December 14, 2023 – Oregon psilocybin laboratory rules. The Oregon Environmental Laboratory Accreditation Program (ORELAP) has announced an open invitation for the public to join a Rules Advisory Committee (RAC) meeting. Scheduled for January 18, 2024, the virtual meeting will address proposed rule changes affecting cannabis and psilocybin testing laboratories.
ORELAP is seeking diverse committee members to provide insights into the Notice of Proposed Rulemaking. This input will help the program understand the fiscal impact of the proposed changes.
Key proposed amendments include:
- Mandatory licensure maintenance by Oregon Psilocybin Services or the Oregon Liquor and Cannabis Commission.
- Incorporating agency guidance into rules regarding the preparation of infused pre-rolls.
- Requiring an internal amplification control for polymerase chain reaction analyses in testing microbiological contaminants.
- Clarification on reporting methods for finished inhalable cannabinoid products.
- Specific sample retention requirements for cannabis testing labs.
- Exemptions and additional reporting requirements for cannabis or psilocybin testing under the 2016 TNI Standard.
- Introduction of mycotoxins in the required analyses for biological tissue proficiency tests.
- Guidelines for accepting psilocybin-containing material from unlicensed entities.
ORELAP emphasizes the importance of diversity and equity in RAC membership, encouraging representation from priority populations, including communities of color, tribal communities, immigrants, refugees, farmworkers, low-income individuals, persons with disabilities, and LGBTQ+ individuals.
Interested parties can contact Steven Jetter, Program Analyst 4, at steven.jetter@oha.oregon.gov to express interest or ask questions. Responses are due by December 29, 2023.
ORELAP’s initiative aligns with the Oregon Health Authority’s goal of creating equitable administrative rules, ensuring diverse community representation in the decision-making process. The upcoming RAC meeting represents a significant step towards more inclusive and comprehensive regulatory standards in the cannabis and psilocybin industries.
